Seven more health apps obtained reimbursement in Germany since February 2024

In Gemany, health apps that can be prescribed by physicians and psychotherapists and reimbursed by health insurers are included in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM). As of March 10, 2025, a total of 59 health apps are available in the Directory and thus reimbursable. 

Between late February 2024 and early March 2025, seven new health apps were introduced in the DiGA Directory. Some examples are provided below.

On April 14, 2024, the “Kranus Lutera” health app was introduced to the Directory. Developed by Kranus Health GmbH, Germany, it offers a 12-week personalized therapy program for men with symptoms of frequent urination due to benign prostate hyperplasia and overactive bladder. The app includes a urination diary, personalized fluid intake tracking, and intelligent cues to help users better understand their patterns. It also features pelvic floor and physiotherapy exercises, cognitive behavioral therapy (CBT) for bladder training, and weekly audio-guided mental exercises. The app is available in German at a tariff of €670.49.

On June 16, 2024, “My Dose Coach” was added to the Directory. Developed by METEDA s.r.l., Italy, this digital application facilitates basal insulin titration through a web portal for healthcare professionals and a companion app for patients. Physicians could create individualized dose plans, review titration results, and adjust dosages as needed. The app guided patients in determining the next insulin dosage step based on fasting blood glucose values and physician-set plans. Initially available in German at a tariff of €478.80, “My Dose Coach” was delisted on January 10, 2025, at the manufacturer’s request.

On February 18, 2025, “elona explore – für die mentale Gesundheit” was introduced to the Directory. Developed by Elona Health GmbH, Germany, this application supports individuals with depression, anxiety, panic disorders, and adjustment disorders. It integrates evidence-based psychotherapeutic interventions and psychoeducational resources based on CBT principles, offering both symptom-specific and vulnerability-focused support. Designed for independent use, the app complements psychiatric and general medical care and can serve as an interim solution while awaiting psychotherapy. It is available in German at a tariff of €535.49.

The other apps introduced in the Directory concerned the management of chronic insomnia, orthopedic and urologic diseases.

The full details in German can be found here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.